<DOC>
	<DOCNO>NCT01639378</DOCNO>
	<brief_summary>The REACH study , prospective , double-blinded , randomise , control study safety effectiveness renal denervation subject chronic systolic heart failure . Bilateral denervation perform use Symplicity Catheter - percutaneous system delivers radio frequency ( RF ) energy luminal surface renal artery .</brief_summary>
	<brief_title>Renal Artery Denervation Chronic Heart Failure Study</brief_title>
	<detailed_description>Interventional study Allocation : Randomised Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double blind ( Subject / CHF team ) . The interventional operator , role care patient follow randomisation . Primary Purpose : Treatment Chronic Systolic Heart Failure Device : Renal denervation ( Symplicity Catheter System ) Symplicity Catheter System -Intervention : Device : Renal denervation ( Symplicity Catheter System ) Patients randomise cath lab receive either renal denervation sham procedure . Experimental arm : Renal Denervation Control arm : No renal denervation ( sham procedure ) In arm , aftercare provide clinician blind randomised allocation arm . Subjects recruit stable heart failure therapy , intention maintain therapy steady followup .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>Chronic heart failure due systolic dysfunction New York Heart Association class II high Maximal pharmacological therapy include ( clinically indicate tolerate ) , bblocker , ACE inhibitor /A2 blocker , Aldosterone blockade . Ejection fraction le 40 % Estimated GFR &lt; 35ml/hr Unfavourable renal anatomy ( renal artery stenosis ) Unable walk treadmill cardiopulmonary exercise test Significant valvular disease ( moderate aortic regurgitation/stenosis mitral stenosis ; severe mitral/tricuspid regurgitation ) Severe lung disease Symptomatic orthostatic dizziness Unable consent Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>